Logo image
Effects of Bepridil Hydrochloride on Cardiocirculatory Dynamics, Coronary Vascular Resistance, and Cardiac Output Distribution in Normal, Conscious Rats
Journal article   Open access   Peer reviewed

Effects of Bepridil Hydrochloride on Cardiocirculatory Dynamics, Coronary Vascular Resistance, and Cardiac Output Distribution in Normal, Conscious Rats

Stephen Flaim, Maria Stranieri and Joanne Mathiasen
Journal of cardiovascular pharmacology, v 11(3), pp 363-372
Mar 1988
PMID: 2452931
url
https://doi.org/10.1097/00005344-198803000-00015View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

The purpose of this study was to characterize he cardiocirculatory effects of bepridil hydrochloride BP) in the normal, conscious rat. Animals were instrumented under halothane anesthesia for right atrial, left perticular, arterial, and venous pressure recordings. The adioactive-microsphere technique was used to measure Regional blood flow and cardiac output before (control) and during intravenous (i.v.) infusion of either BP at three dosage levels (3.0, 6.0, 12.0 mg/kg) or vehicle (VH) it infusion rates matching those of the BP protocol 0.0408 ml/min). The predominant effects of BP (cumulative dose = 9.0 mg/kg i.v.) in the conscious rat were reluced coronary vascular resistance and heart rate. BP showed selectivity for the coronary circulation since systemic vascular resistance was not significantly reduced until a cumulative i.v. dosage of 21.0 mg/kg was administered. BP had few effects on other regions of the peripheral circulation. BP (21 mg/kg) reduced blood flow and increased vascular resistance in the arterial circulations of four of six skeletal muscles studied although opposite effects occurred in two of six muscles studied. BP had no significant effect on blood flow or vascular resistance in the other major arterial circulations. The results of this study show that BP is a selective coronary vasodilator that also reduces the primary indices of myocardial oxygen demand. These results suggest that the clinical therapeutic antianginal efficacy of BP occurs through a combined effect to increase myocardial oxygen supply and to reduce myocardial oxygen demand.

Metrics

8 Record Views
3 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cardiac & Cardiovascular Systems
Pharmacology & Pharmacy
Logo image